Author:
Chen Zailin,Cheng Xianfeng,Wang Xingyu,Ni Shijun,Yu Qiulian,Hu Junchun
Abstract
AbstractIn this study, the core carcinogenic elements in Xuanwei Formation coal were identified. Thirty-one samples were collected based on the age-standardized mortality rate (ASMR) of lung cancer; Si, V, Cr, Co, Ni, As, Mo, Cd, Sb, Pb, and rare earth elements and yttrium (REYs) were analyzed and compared; multivariate statistical analyses (CA, PCA, and FDA) were performed; and comprehensive identification was carried out by combining multivariate statistical analyses with toxicology and mineralogy. The final results indicated that (1) the high-concentration Si, Ni, V, Cr, Co, and Cd in coal may have some potential carcinogenic risk. (2) The concentrations of Cr, Ni, As, Mo, Cd, and Pb meet the zoning characteristics of the ASMR, while the Si concentration is not completely consistent. (3) The REY distribution pattern in Longtan Formation coal is lower than that in Xuanwei Formation coal, indicating that the materials of these elements in coal are different. (5) The heatmap divides the sampling sites into two clusters and subtypes in accordance with carcinogenic zoning based on the ASMR. (6) PC1, PC2, and PC3 explain 62.629% of the total variance, identifying Co, Ni, As, Cd, Mo, Cr, and V. (7) Fisher discriminant analysis identifies Ni, Si, Cd, As, and Co based on the discriminant function. (8) Comprehensive identification reveals that Ni is the primary carcinogenic element, followed by Co, Cd, and Si in combination with toxicology. (9) The paragenesis of Si (nanoquartz), Ni, Co, and Cd is an interesting finding. In other words, carcinogenic elements Ni, Co, Cd, and Si and their paragenetic properties should receive more attention.
Funder
Engineering Center of Yunnan Education Department for Health Geological Survey & Evaluation
Sichuan Natural Science Foundation Project
Everest scientific research program of Chengdu University of Technology
Publisher
Springer Science and Business Media LLC
Reference150 articles.
1. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129–2139 (2004).
2. Rudin, C. M., Brambilla, E., Faivre-Finn, C. & Sage, J. Small-cell lung cancer. Nat. Rev Dis. Primers. 7(1), 1–20 (2021).
3. Sharma, R. Mapping of global, regional and national incidence, mortality and mortality-to incidence ratio of lung cancer in 2020 and 2050. Int. J. Clin. Oncol. 27, 665–675 (2022).
4. Bray, F. et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 1, 1 (2018).
5. Liu, D. H., Jiang, D. M., Zhou, X. M., et al. Comparison of lung cancer mortality between rural and urban areas in the mainland of China from 2004 to 2018. Shanghai J. Prev. Med. 33(10), 893–898 (2021) (In Chinese).